Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS).

导出 LinkOut

翻译打印收藏纠错

作者： Anna,Shalman ^[1] ; Shiri,Savir ^[2] ; Yana,Mechnik Steen ^[3] ; Andrey,Ovanyan ^[4] ; Nancy,Boniel ^[5] ; Leonid,Koyfman ^[1] ; Yoav,Bichovsky ^[1] ; Alexander,Zlotnik ^[1] ; Moti,Klein ^[6] ; Evgeni,Brotfain ^[1]

作者单位： Department of Anesthesiology and Critical Care, General Intensive Care Unit, Soroka Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel. ^[1] Department of Anesthesiology and Critical Care, General Intensive Care Unit, Soroka Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel. Electronic address: yona.shiri@gmail.com. ^[2] Department of Neurology Soroka Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel. Electronic address: yaname@clalit.org.il. ^[3] Department of Neurology Soroka Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel. Electronic address: andreyov@clalit.org.il. ^[4] Department of Radiology, Soroka Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel. ^[5] Department of Anesthesiology and Critical Care, General Intensive Care Unit, Soroka Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel. Electronic address: motik@clalit.org.il. ^[6]

关键词 Guillain-Barre Syndrome Hypoalbuminemia Intravenous Immunoglobulin Serum albumin